TIDES: Oligonucleotide and Peptide® Therapeutics from Research through Commercialization will take place May 12-15, 2013 in Boston, Massachusetts. For more information on this session and the rest of the program, download the agenda. If you'd like to join us as a reader of this blog, when you register to join us and mention code TIDES13JP, you'll receive a discount of 20% off the standard rate.
Featured Session from Novel Chemistries and PK/PD Modulation:
Session: Automated Parallel Solid-phase Synthesis of 5’-triphosphate and 5’-diphosphate Oligonucleotides – Useful Tools for Therapeutics and Diagnostics Applications
Speaker: Ivan Zlatev, Ph.D., Scientist, Ontorii Inc.
About the session: A fully automated method for the parallel and high-throughput synthesis of 5’-triphosphate and 5’-diphosphate oligonucleotides is presented. The desired full-length oligonucleotides were constructed using standard DNA/RNA synthesis. Then, an uninterrupted sequential cycle afforded the unmodified or chemically modified 5’-triphosphates and 5’-diphosphates, useful tools in number of therapeutics and diagnostics applications.
Session: Amino-LNA Modulates the Pharmacokinetic Properties of Therapeutic Oligonucleotides
Speaker: Jesper Wengel, Ph.D., Professor and Center Director, Nucleic Acid Center, University of Southern Denmark, Denmark
About the session: Therapeutic LNA-based oligonucleotide candidates have been modified with amino-LNA derivatives. This lecture highlights how defined amino-LNA nucleotides may be used to, e.g., increase lipofilicity or modulate the overall charge of antisense, siRNA and antimir constructs. Results from in vivo studies will be presented demonstrating the appealing potential of amino-LNA nucleotides to modulate the pharmacokinetic properties of therapeutic oligonucleotides.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment